Home › VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
 

Keywords :   


VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

2014-11-17 17:45:00| Merck.com - Product News

Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the events study reduced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Remnants of Fourteen-E Graphics
07.11Remnants of Fourteen-E Forecast Discussion Number 6
07.11Remnants of Fourteen-E Wind Speed Probabilities Number 6
07.11Remnants of Fourteen-E Public Advisory Number 6
07.11Summary for Remnants of Fourteen-E (EP4/EP142024)
07.11Remnants of Fourteen-E Forecast Advisory Number 6
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Advisory Number 17
More »